Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.
Primary Language | English |
---|---|
Subjects | Internal Diseases |
Journal Section | Case Reports |
Authors | |
Publication Date | April 1, 2022 |
Submission Date | February 10, 2022 |
Acceptance Date | March 9, 2022 |
Published in Issue | Year 2022 Volume: 4 - Supplement 1 |